Table 1.
Patients’ characteristics and comparison of outcomes.
| All Patients (n = 92) |
Double Hit (n = 14) |
Non-Double Hit (n = 78) |
p-Value | |
|---|---|---|---|---|
| Gender, n (%) | 0.909 a | |||
| Male | 48 (52.2%) | 8 (57.1%) | 40 (51.3%) | |
| Female | 44 (47.8%) | 6 (42.9%) | 38 (48.7%) | |
| Age when diagnosed, n (%) | 0.518 a | |||
| <65 | 50 (54.3%) | 6 (42.9%) | 44 (56.4%) | |
| ≥65 | 42 (45.7%) | 8 (57.1%) | 34 (43.6%) | |
| Performance status, n (%) | 0.060 b | |||
| ≤2 | 81 (88.0%) | 10 (71.4%) | 71 (91.0%) | |
| >2 | 11 (12.0%) | 4 (28.6%) | 7 (9.0%) | |
| Stage, n (%) | 0.134 b | |||
| Limited (Stage 1–2) | 30 (32.6%) | 2 (14.3%) | 28 (35.9%) | |
| Advanced (Stage 3–4) | 62 (67.4%) | 12 (85.7%) | 50 (64.1%) | |
| Bulky disease, n (%) | 0.013 b | |||
| No | 61 (66.3%) | 5 (35.7%) | 56 (71.8%) | |
| Yes | 31 (33.7%) | 9 (64.3%) | 22 (28.2%) | |
| R-IPI score, n (%) | 0.640 a | |||
| Lower risk (0–2) | 48 (52.2%) | 6 (42.9%) | 42 (53.8%) | |
| Higher risk (3–5) | 44 (47.8%) | 8 (57.1%) | 36 (46.2%) | |
| LDH (U/L), median (range) | 315 (111–4461) | 360 (169–1760) | 303 (111–4461) | 0.277 c |
| Uric acid (mg/dL), median (range) | 5.5 (1.5–19.0) | 5.2 (3.5–16.4) | 5.6 (1.5–19.0) | 0.721 c |
| Maximal SUV (/1 h), median (range) | 12.6 (2.5–27.4) | 13.1 (4.1–25.2) | 12.4 (2.5–27.4) | 0.436 c |
| CCI score, median (range) | 4 (2–11) | 5 (2–11) | 4 (2–11) | 0.659 c |
| Double expresser, n (%) | 0.044 b | |||
| No | 68 (73.9%) | 7 (50.0%) | 61 (78.2%) | |
| Yes | 24 (26.1%) | 7 (50.0%) | 17 (21.8%) | |
| Cell of origin, n (%) | 0.122 b | |||
| GCB | 30 (34.1%) | 7 (53.8%) | 23 (30.7%) | |
| Non-GCB | 58 (65.9%) | 6 (46.2%) | 52 (69.3%) | |
| Treatment, n (%) | 0.501 a | |||
| R + intensified chemotherapy | 13 (14.1%) | 2 (14.3%) | 11 (14.1%) | |
| R-CHOP | 65 (70.7%) | 8 (57.1%) | 57 (73.1%) | |
| R-COP | 7 (7.6%) | 2 (14.3%) | 5 (6.4%) | |
| Palliative care | 7 (7.6%) | 2 (14.3%) | 5 (6.4%) | |
| Treatment response, n (%) | 0.687 a | |||
| Non-CR | 31 (36.5%) | 5 (41.7%) | 26 (35.6%) | |
| CR | 54 (63.5%) | 7 (58.3%) | 47 (64.4%) | |
| Mortality, n (%) | 0.028 a | |||
| Alive | 54 (58.7%) | 4 (28.6%) | 50 (64.1%) | |
| Death | 38 (41.3%) | 10 (71.4%) | 28 (35.9%) | |
| Causes of death, n (%) | 0.663 a | |||
| Disease related | 22 (57.9%) | 7 (70.0%) | 15 (53.6%) | |
| Complication | 11 (28.9%) | 2 (20.0%) | 9 (32.1%) | |
| Others | 5 (13.2%) | 1 (10.0%) | 4 (14.3%) |
Data were compared using a Chi-square test, b Fisher’s Exact test, and c Mann–Whitney U test. LDH: lactate dehydrogenase; SUV: standardized uptake value; CCI: Charlson comorbidity index; GCB: germinal center B-cell; R: rituximab; CR: complete remission.